PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19328214-4 2009 HTC cells were found to be sensitive to exogenous ceramide and significantly protected against TNF by desipramine, an inhibitor of lysosomal acid sphingomyelinase. Desipramine 102-113 tumor necrosis factor Rattus norvegicus 95-98 17477857-16 2007 In vitro, desipramine and fluoxetine dose-dependently inhibited the release of TNF-alpha from LPS-treated monocytes. Desipramine 10-21 tumor necrosis factor Rattus norvegicus 79-88 18791062-9 2008 Desipramine at the dose of 20 mg/kg produced more decrease in the level of TNF-alpha compared with the effect of the smaller dose, but fluoxetine at 10 mg/kg diminished more in the level of IL-1beta compared with the effect of the larger dose. Desipramine 0-11 tumor necrosis factor Rattus norvegicus 75-84 18791062-8 2008 Desipramine and fluoxetine, at either dose, significantly reduced TNF-alpha and IL-beta. Desipramine 0-11 tumor necrosis factor Rattus norvegicus 66-75 10808050-6 2000 Chronic (14 days) administration of the antidepressant drugs desipramine or zimelidine transforms alpha(2)-adrenergic receptor-dependent decreases in TNF levels to increases in levels of TNF in the locus coeruleus. Desipramine 61-72 tumor necrosis factor Rattus norvegicus 150-153 10808050-6 2000 Chronic (14 days) administration of the antidepressant drugs desipramine or zimelidine transforms alpha(2)-adrenergic receptor-dependent decreases in TNF levels to increases in levels of TNF in the locus coeruleus. Desipramine 61-72 tumor necrosis factor Rattus norvegicus 187-190 9357451-7 1997 After administration of the tricyclic antidepressant desipramine, tissue sections obtained from the rat hippocampus and locus coeruleus are devoid of neuronal-associated TNF alpha immunoreactivity. Desipramine 53-64 tumor necrosis factor Rattus norvegicus 170-179 7895065-2 1994 Antidepressant administration of desipramine to rats twice-daily for 2 weeks increased hippocampal TNF levels and transformed the presynaptic TNF response. Desipramine 33-44 tumor necrosis factor Rattus norvegicus 99-102 7895065-2 1994 Antidepressant administration of desipramine to rats twice-daily for 2 weeks increased hippocampal TNF levels and transformed the presynaptic TNF response. Desipramine 33-44 tumor necrosis factor Rattus norvegicus 142-145 7895065-3 1994 One day of desipramine administration resulted in increased locus coeruleus TNF mRNA accumulation and, simultaneously, hippocampal TNF levels escalated. Desipramine 11-22 tumor necrosis factor Rattus norvegicus 76-79 7895065-3 1994 One day of desipramine administration resulted in increased locus coeruleus TNF mRNA accumulation and, simultaneously, hippocampal TNF levels escalated. Desipramine 11-22 tumor necrosis factor Rattus norvegicus 131-134 7895065-6 1994 In addition, TNF potentiation of [3H]norepinephrine release after chronic desipramine administration was reversed in the presence of idazoxan to a greater inhibition than in control slices exposed to idazoxan. Desipramine 74-85 tumor necrosis factor Rattus norvegicus 13-16 15082752-1 2004 The present study documents a role for brain-derived tumor necrosis factor-alpha (TNF) in the mechanism of action of the antidepressant drug desmethylimipramine (desipramine). Desipramine 141-160 tumor necrosis factor Rattus norvegicus 82-85 15082752-1 2004 The present study documents a role for brain-derived tumor necrosis factor-alpha (TNF) in the mechanism of action of the antidepressant drug desmethylimipramine (desipramine). Desipramine 162-173 tumor necrosis factor Rattus norvegicus 82-85 15082752-3 2004 Chronic desipramine administration transforms TNF-mediated inhibition of NE release to facilitation, dependent upon alpha2-adrenergic receptor activation. Desipramine 8-19 tumor necrosis factor Rattus norvegicus 46-49 15082752-6 2004 To determine whether this transformation is due to desipramine-induced inhibition of TNF bioactivity in the brain, rats were i.c.v. Desipramine 51-62 tumor necrosis factor Rattus norvegicus 85-88 15082752-10 2004 Although simultaneous microinfusion of rrTNF with chronic desipramine administration prevents the transformation induced by desipramine, microinfusion of rrTNF enhances TNF inhibition of NE release. Desipramine 124-135 tumor necrosis factor Rattus norvegicus 41-44 15082752-17 2004 microinfusion of rrTNF with concomitant desipramine administration opposes decreases in neuron-associated TNF levels, required to transform presynaptic sensitivity to TNF, which is necessary for the drug to be efficacious. Desipramine 40-51 tumor necrosis factor Rattus norvegicus 106-109 11303058-3 2001 Immunohistochemical analysis and in situ hybridization reveal that administration of the antidepressant drug desipramine decreases the accumulation of constitutively expressed TNF mRNA in neurons of the rat brain. Desipramine 109-120 tumor necrosis factor Rattus norvegicus 176-179 10601816-9 2000 Vehicle treated OB rats displayed a significant impairment in LPS-induced IL-1beta (54%) and TNF-alpha (70%) secretion compared to their sham operated controls, an effect that was potentiated following chronic desipramine treatment. Desipramine 210-221 tumor necrosis factor Rattus norvegicus 93-102 10601816-10 2000 Furthermore, sham animals that were chronically treated with desipramine displayed decreases in LPS-provoked IL-1beta (51%) and TNF-alpha (49%) secretion compared to vehicle treated counterparts. Desipramine 61-72 tumor necrosis factor Rattus norvegicus 128-137 10601816-13 2000 Whilst chronic treatment with desipramine normalized the behavioural hyperactivity observed in OB rats, such treatment further impaired LPS-induced IL-1beta and TNF-alpha secretion in bulbectomized rats. Desipramine 30-41 tumor necrosis factor Rattus norvegicus 161-170